Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe
In real‑world European practice, most patients with malignant pleural mesothelioma (MPM) receive platinum‑antifolate doublet chemotherapy as first‑line treatment; maintenance therapy is commonly used despite absence of approved regimens, and the disease still exerts a high humanistic burden on patients’ quality of life.
Background: Malignant pleural mesothelioma (MPM) is an aggressive and rare tumour with poor prognosis. Most patients are diagnosed with advanced disease and there is a paucity of data on the humanistic burden of MPM in terms of impact on health‑related quality of life (HRQoL) and activity. This study examined real‑world treatment patterns and humanistic disease burden of MPM in Europe. Methods: Physicians abstracted demographic/clinical characteristics and treatment data from MPM‑patient medical records; MPM patients self‑completed a questionnaire including symptoms, 3‑level‑EQ‑5D, Visual Analogue Scale (VAS), Lung Cancer Symptom Scale for Mesothelioma (LCSS‑Meso), and Work Productivity and Activity Impairment (WPAI). Results: Physicians (n = 171) abstracted data of 1390 patients; 767/1390 patients self‑completed questionnaires. Patients were elderly with advanced, unresectable MPM. Treatment patterns followed guidelines with most (81%) patients receiving platinum+antifolate chemotherapy at first line (1 L). Maintenance treatment use was high (51.1%) despite no recommended maintenance therapies. Symptom burden was high and health states and HRQoL were poor at 1; declining further with progression. Conclusion: The humanistic burden of MPM is high, despite treatments being prescribed as per available guidance. Treatments that delay progression and provide palliation of symptoms are most likely to improve/maintain HRQoL.
Because MPM patients experience significant deterioration in health‑related quality of life and functional status, interventions that can alleviate symptoms and improve HRQoL are essential for a disease with limited survival and few curative options.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma